Ameritas Advisory Services’s Catalyst Pharmaceutical CPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$386K Buy
+15,596
New +$372K 0.02% 669
2023
Q1
Sell
-58,599
Closed -$1.09M 2721
2022
Q4
$1.09M Buy
+58,599
New +$902K 0.05% 328

Other funds holding CPRX

Ameritas Advisory Services's CPRX Position: Q1 2026 in Review

Ameritas Advisory Services opened a new position in Catalyst Pharmaceutical (CPRX) in Q1 2026: 15,596 shares worth $386K. The stake represents 0.02% of the portfolio and ranks #669 among its holdings. This is a return to the name: Ameritas Advisory Services previously reported a position in CPRX as recently as Q4 2022.

Ameritas Advisory Services first reported a position in CPRX in Q4 2022 and has held it in 2 quarters since. The position peaked at $1.09M in Q4 2022. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Ameritas Advisory Services held 15,596 shares of Catalyst Pharmaceutical worth $386K as of Q1 2026.
  • Catalyst Pharmaceutical was a new Ameritas Advisory Services position in Q1 2026.
  • Catalyst Pharmaceutical made up 0.02% of Ameritas Advisory Services's portfolio in Q1 2026, its #669 holding.
  • Ameritas Advisory Services first reported a position in Catalyst Pharmaceutical in Q4 2022 and has held it in 2 quarters since.
  • Ameritas Advisory Services's Catalyst Pharmaceutical position peaked at $1.09M in Q4 2022.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Ameritas Advisory Services's 13F filing for Q1 2026, filed 12 May 2026.